Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO

Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, is seeking to raise $212.4 million in a US initial public offering.

The Boston-based company plans to market 11.8 million shares for $16 to $18 each, according to its filing Monday with the US Securities and Exchange Commission. At the top of that range, the biotech would have a market value of $912 million based on the outstanding shares listed in its filing.

Seaport expects to release second phase trial results for its lead drug, a treatment for major depressive disorder, in the first half of ...